Paritaprevir
CAS No. 1216941-48-8
Paritaprevir( ABT-450 | Veruprevir )
Catalog No. M10813 CAS No. 1216941-48-8
Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 79 | Get Quote |
|
| 5MG | 132 | Get Quote |
|
| 10MG | 168 | Get Quote |
|
| 25MG | 302 | Get Quote |
|
| 50MG | 492 | Get Quote |
|
| 100MG | 710 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameParitaprevir
-
NoteResearch use only, not for human use.
-
Brief DescriptionParitaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively.
-
DescriptionParitaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively; demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50=0.09 to 19 nM), and an EC50 of 0.09 nM against GT4a; The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.HCV Infection Approved.
-
In VitroParitaprevir has in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a.
-
In VivoThe combination of Paritaprevir, Ritonavir, Ombitasvir (an NS5A protein inhibitor), and Dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.The acute toxicity of Paritaprevir is considered to be low. Single oral doses of ≤600 mg/kg in rats and ≤100 mg/kg in dogs produces no mortality and were well tolerated. However, since Paritaprevir is administered without ritonavir as a PK enhancer, the exposures are low, especially in male rats (rat 600 mg/kg, males: Cmax 1.82 μg/mL, AUC0-24 8.89 μg·h/mL; dog 100 mg/kg, mean: Cmax 61.3 μg/mL, AUC0-24 285 μg·h/mL).
-
SynonymsABT-450 | Veruprevir
-
PathwayMicrobiology/Virology
-
TargetHCV
-
RecptorHCV
-
Research AreaInfection
-
IndicationHCV Infection
Chemical Information
-
CAS Number1216941-48-8
-
Formula Weight765.8771
-
Molecular FormulaC40H43N7O7S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C([C@]([C@]1([H])/C=C\CCCCC[C@@H]2NC(C3=NC=C(C)N=C3)=O)(C1)NC([C@@](C[C@@H](OC4=C5C=CC=CC5=C(C=CC=C6)C6=N4)C7)([H])N7C2=O)=O)NS(=O)(C8CC8)=O
-
Chemical NameCyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16a
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schnell G, et al. Antimicrob Agents Chemother. 2015 Nov;59(11):6807-15.
2. Carrion AF, et al. Expert Opin Pharmacother. 2014 Apr;15(5):711-6.
3. Zeuzem S, et al. N Engl J Med. 2014 Apr 24;370(17):1604-14.
4. Andreone P, et al. Gastroenterology. 2014 Aug;147(2):359-365.e1.
molnova catalog
related products
-
Tegobuvir
A nonnucleoside inhibitor of HCV NS5B polymerase that acts as a potent inhibitor of HCV genotype 1.
-
Daclatasvir
A potent HCV NS5A inhibitor with EC50 of <50 pM against genotype 1 replicons.
-
Beta-d-N4-hydroxycyt...
Beta-d-N4-hydroxycytidine (NHC) is a nucleoside analogue that has antipestivirus and antihepacivirus activities.
Cart
sales@molnova.com